Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
127.65
+0.07 (0.05%)
Aug 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 127.27 - 129.01
52 week 96.93 - 139.00
Open 127.43
Vol / Avg. 4.27M/3.33M
Mkt cap 99.92B
P/E 39.70
Div/yield     -
EPS 3.22
Shares 782.35M
Beta 1.89
Inst. own 80%
Oct 25, 2017
Q3 2017 Celgene Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 13, 2017
Celgene Corp at Morgan Stanley Healthcare Conference - 9:20AM EDT - Add to calendar
Aug 9, 2017
Celgene Corp at Canaccord Genuity Growth Conference - Webcast
Jul 27, 2017
Q2 2017 Celgene Corp Earnings Release
Jul 27, 2017
Q2 2017 Celgene Corp Earnings Call - Webcast
Jul 6, 2017
BeiGene Ltd and Celgene Corp Global Strategic Collaboration Call
Jun 15, 2017
Celgene Corp Annual Shareholders Meeting (Estimated)
Jun 14, 2017
Celgene Corp Annual Shareholders Meeting
May 31, 2017
Celgene Corp at Sanford C Bernstein Strategic Decision Conference - Webcast
May 23, 2017
Celgene Corp at UBS Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 32.47% 17.80%
Operating margin 38.65% 25.02%
EBITD margin - 33.76%
Return on average assets 14.40% 7.26%
Return on average equity 52.90% 31.94%
Employees 7,132 -
CDP Score - B

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Officers and directors

Robert J. Hugin Executive Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott A. Smith President, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Mark J. Alles Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Terrie Curran President, Global Inflammation & Immunology Franchise
Age: 48
Bio & Compensation  - Reuters
Michael F. Pehl President, Hematology & Oncology
Age: 52
Bio & Compensation  - Reuters
Rupert J. Vessey President - Research and Early Development
Age: 52
Bio & Compensation  - Reuters
Gerald F. Masoudi Executive Vice President, General Counsel and Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 58
Bio & Compensation  - Reuters